Analysts Issue Forecasts for argenx SE’s Q3 2025 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Research analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of argenx in a research note issued to investors on Friday, July 26th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $1.38 for the quarter, up from their prior forecast of $1.19. HC Wainwright has a “Buy” rating and a $533.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for argenx’s Q4 2025 earnings at $0.75 EPS and FY2027 earnings at $31.39 EPS.

Several other equities research analysts have also commented on ARGX. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “hold” rating to a “buy” rating in a report on Thursday, July 25th. William Blair restated a “market perform” rating on shares of argenx in a report on Monday, June 17th. Wedbush boosted their price target on shares of argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a report on Friday, July 26th. JPMorgan Chase & Co. cut their price objective on shares of argenx from $560.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, May 13th. Finally, Truist Financial lifted their price objective on shares of argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $540.37.

argenx Stock Performance

NASDAQ:ARGX opened at $509.21 on Monday. argenx has a one year low of $327.73 and a one year high of $532.59. The firm has a market cap of $30.45 billion, a P/E ratio of -89.97 and a beta of 0.64. The firm has a 50-day simple moving average of $421.43 and a 200-day simple moving average of $396.68.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The company had revenue of $489.43 million during the quarter, compared to analyst estimates of $436.66 million. During the same quarter last year, the business posted ($1.69) EPS.

Institutional Trading of argenx

Several large investors have recently bought and sold shares of the stock. J.Safra Asset Management Corp boosted its holdings in shares of argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the last quarter. Mather Group LLC. purchased a new stake in shares of argenx in the 1st quarter valued at $38,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in shares of argenx in the 4th quarter valued at $60,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.